Circulating and disseminated tumor cells in the management of breast cancer
- PMID: 19605818
- DOI: 10.1309/AJCPJI7DEOLKCS6F
Circulating and disseminated tumor cells in the management of breast cancer
Abstract
Despite the advances in early detection and treatment of cancer, patients continue to die of the disease even when they seek care at an early stage. For patients with breast cancer, it is now possible to detect circulating tumor cells (CTCs) in the bloodstream and disseminated tumor cells (DTCs) in the bone marrow by using immunocytochemical and molecular methods. CTCs and DTCs have been found to share similar genotypic and phenotypic characteristics with so-called breast cancer stem cells, a finding that could potentially explain the eventual relapse of disease in a patient previously considered to have been cured by primary therapy. In some studies, the presence of CTCs or DTCs at the time of diagnosis of breast cancer is an independent adverse prognostic variable. However, before CTC/DTC testing can achieve standard-of-care status, there must be improvement in the sensitivity, precision, and reproducibility of the detection methods.
Similar articles
-
Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.Pathobiology. 2008;75(2):140-8. doi: 10.1159/000123852. Epub 2008 Jun 10. Pathobiology. 2008. PMID: 18544969 Review.
-
Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?Expert Rev Anticancer Ther. 2007 Oct;7(10):1463-72. doi: 10.1586/14737140.7.10.1463. Expert Rev Anticancer Ther. 2007. PMID: 17944570 Review.
-
Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.Clin Cancer Res. 2008 Jun 1;14(11):3306-11. doi: 10.1158/1078-0432.CCR-07-4749. Clin Cancer Res. 2008. PMID: 18519757
-
Role of circulating tumor cells and disseminated tumor cells in primary breast cancer.Breast Cancer. 2012 Apr;19(2):110-7. doi: 10.1007/s12282-011-0282-5. Epub 2011 Jun 4. Breast Cancer. 2012. PMID: 21643809 Review.
-
Circulating tumor cells and bone marrow micrometastasis.Clin Cancer Res. 2008 Aug 15;14(16):5013-21. doi: 10.1158/1078-0432.CCR-07-5125. Clin Cancer Res. 2008. PMID: 18698019 Review.
Cited by
-
Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.PLoS One. 2013;8(2):e56836. doi: 10.1371/journal.pone.0056836. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418605 Free PMC article.
-
Myeloid derived suppressor cells and the release of micro-metastases from dormancy.Clin Exp Metastasis. 2021 Jun;38(3):279-293. doi: 10.1007/s10585-021-10098-8. Epub 2021 May 20. Clin Exp Metastasis. 2021. PMID: 34014424 Free PMC article. Review.
-
Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.BMC Cancer. 2011 Jan 31;11:47. doi: 10.1186/1471-2407-11-47. BMC Cancer. 2011. PMID: 21281486 Free PMC article. Clinical Trial.
-
Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A review.Clujul Med. 2016;89(2):203-11. doi: 10.15386/cjmed-570. Epub 2016 Apr 15. Clujul Med. 2016. PMID: 27152069 Free PMC article. Review.
-
Low Levels of Sox2 are required for Melanoma Tumor-Repopulating Cell Dormancy.Theranostics. 2019 Jan 1;9(2):424-435. doi: 10.7150/thno.29698. eCollection 2019. Theranostics. 2019. PMID: 30809284 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical